Comparative Pharmacology
Head-to-head clinical analysis: SUMAVEL DOSEPRO versus ZOMIG ZMT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUMAVEL DOSEPRO versus ZOMIG ZMT.
SUMAVEL DOSEPRO vs ZOMIG-ZMT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sumatriptan is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, causing vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial blood vessels, inhibits trigeminal nerve transmission, and reduces neurogenic inflammation.
Sumavel DosePro (sumatriptan injection) is administered subcutaneously via a single-use needle-free injector. The typical adult dose is 6 mg subcutaneously once, with a maximum of 6 mg per 24 hours. A second injection may be given at least 1 hour after the first if symptoms recur, but not more than two injections in 24 hours.
2.5 mg orally at onset of migraine; may repeat after 2 hours if needed. Maximum 10 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life is 2.5–3 hours. Clinical context: Short half-life allows titrated dosing; may prolong in hepatic impairment.
Terminal elimination half-life is approximately 3 to 3.5 hours for zolmitriptan and its active metabolite N-desmethyl zolmitriptan has a similar half-life. This supports a typical dosing interval of at least 2 hours between doses.
Primarily renal (60% unchanged, 20% as indole acetic acid metabolite) and fecal (about 10%). Biliary excretion contributes minimally.
Approximately 60-70% of the administered dose is excreted in urine, primarily as metabolites (active N-desmethyl zolmitriptan and inactive indoleacetic acid derivatives), with about 10-15% as unchanged drug. Fecal excretion accounts for about 20-30% of the dose.
Category C
Category C
Triptan Antimigraine
Triptan Antimigraine